jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Apolipoprotein - A1

Heart
image

Report in 4Hrs

image

At Home

fastingrequire

Fasting Required

Details

Apolipoprotein A1 (Apo A1) is the main protein component of High-Density Lipoprotein (HDL), often called the “good cholesterol.”

₹269₹495

46% OFF

Apolipoprotein - A1 (ApoA1) Test Information Guide

  • Why is it done?
    • ApoA1 is the major protein component of high-density lipoprotein (HDL) or 'good cholesterol,' which plays a crucial role in reverse cholesterol transport and cardiovascular protection
    • Assess cardiovascular risk: ApoA1 levels are more specific predictors of cardiovascular disease risk than HDL cholesterol alone
    • Evaluate lipid metabolism disorders: Detect abnormalities in cholesterol and lipoprotein metabolism
    • Monitor familial lipid disorders: Screen for genetic conditions affecting lipoprotein levels such as familial hypoalphalipoproteinemia
    • Evaluate metabolic syndrome: Identify metabolic abnormalities associated with increased cardiovascular risk
    • Performed during routine preventive health screening, especially in patients with family history of premature coronary artery disease or following acute cardiovascular events
  • Normal Range
    • Reference Values: Men: 110-160 mg/dL (2.8-4.1 mmol/L) Women: 120-200 mg/dL (3.0-5.1 mmol/L)
    • Unit of Measurement:mg/dL (milligrams per deciliter) or mmol/L (millimoles per liter)
    • Interpretation:
    • High ApoA1 (>160 mg/dL in men, >200 mg/dL in women): Indicates favorable lipid profile and lower cardiovascular risk; associated with protective effects against atherosclerosis
    • Low ApoA1 (<110 mg/dL in men, <120 mg/dL in women): Indicates reduced HDL function and elevated cardiovascular risk; associated with increased susceptibility to atherosclerotic disease
    • Normal Range: Indicates adequate HDL protective function; optimal cardiovascular risk profile
  • Interpretation
    • Elevated ApoA1 Levels:Associated with increased HDL cholesterol and improved reverse cholesterol transport; may indicate lower cardiovascular risk and better metabolic health
    • Low ApoA1 Levels:May indicate familial hypoalphalipoproteinemia, poor reverse cholesterol transport, increased cardiovascular disease risk, metabolic syndrome, diabetes, or liver disease
    • ApoA1 to ApoB Ratio:Higher ratios suggest more favorable lipid profiles and reduced atherosclerotic risk; this ratio provides superior cardiovascular risk stratification compared to cholesterol values alone
    • Factors Affecting ApoA1 Levels:
    • Lifestyle: Regular exercise and physical activity increase ApoA1; sedentary lifestyle decreases levels
    • Diet: High fiber intake and moderate alcohol consumption increase ApoA1; high refined carbohydrates and trans fats decrease levels
    • Medications: Statins, fibrates, and hormone replacement therapy can modify ApoA1 levels
    • Age and Sex: Women typically have higher ApoA1 levels; levels may change with age and hormonal status
    • Medical Conditions: Liver disease, kidney disease, diabetes, and inflammatory conditions affect levels
    • Clinical Significance:ApoA1 is considered a more reliable predictor of cardiovascular risk than HDL cholesterol alone; it reflects the actual number and function of HDL particles, providing better insight into cardiovascular protection
  • Associated Organs
    • Primary Organ Systems:
    • Cardiovascular System: ApoA1 is essential for HDL function and plays a protective role against atherosclerosis, coronary artery disease, and stroke
    • Liver: Primary site of ApoA1 synthesis; liver disease significantly reduces production and circulating levels
    • Intestines: Secondary source of ApoA1 production; involved in initial lipoprotein assembly
    • Medical Conditions Associated with Abnormal ApoA1:
    • Cardiovascular Disease: Premature coronary artery disease, myocardial infarction, and atherosclerosis associated with low ApoA1
    • Familial Hypoalphalipoproteinemia: Genetic disorder characterized by severely low HDL and ApoA1 levels
    • Type 2 Diabetes: Often associated with reduced ApoA1 and dyslipidemia
    • Metabolic Syndrome: Characterized by low HDL/ApoA1 among other lipid abnormalities
    • Liver Disease: Cirrhosis, hepatitis, and liver dysfunction reduce ApoA1 synthesis
    • Kidney Disease: Chronic renal failure and nephrotic syndrome associated with reduced ApoA1
    • Inflammatory Conditions: Systemic inflammation (rheumatoid arthritis, lupus) reduces HDL and ApoA1
    • Potential Complications of Abnormal Levels:
    • Low ApoA1 increases risk for atherosclerosis, myocardial infarction, stroke, and peripheral vascular disease
    • Impaired reverse cholesterol transport contributes to atherogenic dyslipidemia
  • Follow-up Tests
    • Recommended Additional Tests:
    • Complete Lipid Panel: Total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides for comprehensive cardiovascular risk assessment
    • Apolipoprotein B (ApoB): Measure lipoprotein particles carrying atherogenic lipids; calculate ApoA1:ApoB ratio for improved risk stratification
    • Lipoprotein(a) [Lp(a)]: Assess additional independent cardiovascular risk factor
    • High-Sensitivity C-Reactive Protein (hsCRP): Evaluate systemic inflammation as cardiovascular risk marker
    • Fasting Blood Glucose and HbA1c: Screen for diabetes which affects ApoA1 levels
    • Liver Function Tests: Assess hepatic function if liver disease suspected as cause of low ApoA1
    • Renal Function Tests (BUN, Creatinine): Evaluate kidney function affecting lipoprotein metabolism
    • Electrocardiography (ECG) and Cardiac Imaging: If symptoms suggestive of coronary artery disease or abnormal lipid results warrant cardiovascular evaluation
    • Monitoring Frequency:
    • Low-Risk Patients: Every 5 years as part of routine preventive screening
    • Moderate-Risk Patients: Every 1-2 years or as recommended by healthcare provider
    • High-Risk/Known CVD Patients: Every 6-12 months to monitor treatment response and manage therapy
    • Post-Treatment Monitoring: 4-12 weeks after initiating or modifying lipid-lowering therapy to assess response
    • Complementary Tests:
    • HDL Particle Number and Size: Provides detailed information about HDL quality and function
    • Carotid Intima-Media Thickness (CIMT): Ultrasound assessment of subclinical atherosclerosis
    • Coronary Artery Calcium Score: CT imaging to assess atherosclerotic burden in high-risk patients
  • Fasting Required?
    • Fasting Status:Yes - Fasting is recommended but not always strictly required
    • Fasting Duration:9-12 hours optimal fasting period before blood draw to minimize post-prandial lipid alterations
    • Special Instructions:
    • Avoid eating solid foods for 9-12 hours prior to testing; water intake is permitted
    • Do not consume alcohol for 24 hours before testing as it may affect lipid measurements
    • Caffeine consumption is generally acceptable but should be discussed with healthcare provider
    • Medications:
    • Continue regular medications unless specifically instructed otherwise by healthcare provider
    • Inform laboratory/provider of all current medications as some drugs may influence ApoA1 levels
    • Other Preparation Requirements:
    • Avoid strenuous physical exercise for 24-48 hours before testing as vigorous activity can temporarily elevate lipid levels
    • Minimize stress and ensure adequate sleep night before test; acute stress elevates lipid measurements
    • Maintain consistent diet for several days before testing to ensure reliable baseline measurements
    • Schedule test in morning hours when possible for standardization
    • Bring identification and insurance information; notify provider of recent acute illness or hospitalization

How our test process works!

customers
customers